2423549401

Activity (compared to

Ant i body (generation)	Antibody Specificity				rituximab)		Additional Features
	Type	Isotype	CDR	CDC	ADCC	Apoptosis	(compared to rituximab)	Clinical Trials*	References
Tositumomab Ost)	II	lgG2A	Murine	—	=	+ +	Bound to radioisotopes	Bound to radioisotopes: NHL	9, 73, 75
Ofatumumab (2nd)	I	IgGI	Humań	+ + +			-    Binds the smali extracellular part of CD20 -    Completely human -    Slower off-rate	Phase l/ll: RA, FL, CLL, WM, RRMS Phase III: CLL, FL, DLBCL	10, 76-83
Ocrelizumab (2nd)	I	IgGI	Humanized		=/+		Binds a different but overlapping epitope compared to rituximab	Phase 1, II, III: RA NHL Phase III: SLE Phase II: RRMS	69,91,92
Veltuzumab (2nd)	I	IgGI	Humanized	=/+			Slower off-rate	Phase l/ll: CLL, NHL, ITP	84-90
PROI BI 921	I	lgG1	Humanized	=	++	=	Enhanced affinity for FcyRII	Phase l/ll: CLL, NHL	93, 94
(3rd)
AME-1 33	I	lgG1	Humanized	=	+	=	Enhanced affinity for CD20	Phase l/ll: NHL	95, 96
(3rd)
GAI 01 (Brd)	II	IgGI	Humanized		+++	+++	-    High affinity for FcyRII -    Strong induction of apoptosis	Phase l/ll: NHL	99-112

Abbreviations: CDR, complementary-determining regions; IgG, immunoglobulin; CDC, complement-dependent cytotoxicity; ADCC, antibody-dependent cellular cytotoxicity; RA, rheumatoid arthritis; FL, follicular lymphoma; CLL, chronic lymphocytic leukaemia; RRMS, relapsing remitting multiple sclerosis; WM, Waldenstróm's macroglobulinemia; DLBCL, dlffuse large B-cell lymphoma; SLE, systemie lupus erythematosus; ITP, idiopathic autoimmune thrombocytopenic purpura; NHL, non-Hodgkin lymphoma.

* Ref erence: www.dinicaltrials.gov.